IOL assessment in SCT

• The GITMO suggests that all patients planned for SCT undergo clinical & serological assessment for IOL. Low-risk patients received <20 RBCU, have an SF <1000ng/mL & have been anemic ≤1 year; all others are high risk & should undergo additional screening & assessment of organ function¹.
• Future analyses should include additional endpoints likely to be impacted by IOL following SCT such as risk of atherosclerosis and secondary malignancies^2,3.
• Transfusion history should be tracked routinely.